Everything tagged "cash flow" across research, earnings, and macro.
113 articles
Equifax is evolving from a traditional credit bureau into a proprietary-data and workflow software compounder, with accelerating revenue, strong cash flow, and AI-driven product momentum. The stock looks like a selective Buy, though valuation and leverage keep it from being a no-brainer.
D.R. Horton remains a scale leader in U.S. homebuilding, with strong cash generation and disciplined execution helping offset affordability pressure. The stock looks reasonably valued, with a Buy rating and fair value of $165.
Ubiquiti is pairing 18.7% quarterly revenue growth with 30.4% net margins as its Enterprise Technology mix expands. The stock screens expensive, but the report argues the platform shift and strong cash generation justify a Buy.
Globe Life is a steady compounder with improving health growth, strong cash generation, and a valuation that still looks reasonable versus earnings power.
Shell combines supermajor scale, growing LNG exposure, and strong cash generation with disciplined shareholder returns. The stock looks attractively valued for a cyclical energy name, though commodity and operational risks remain.
British American Tobacco is a medium-term Buy as combustibles keep generating cash while smokeless products, led by Velo, show real operating momentum. The stock looks reasonably valued with a fair value estimate of $68.
Equinor combines strong European gas exposure, a low-cost Norwegian base, and disciplined capital spending into a balanced Buy case. The stock looks fairly valued to slightly undervalued with a $39 fair value estimate.
ConocoPhillips combines elite free cash flow generation with visible project catalysts like Willow and LNG, but earnings still move with oil and gas prices. The report is constructive and rates COP a Buy.
BP looks like a medium-term value and cash-flow story, supported by strong 1Q26 operating momentum and a low forward P/E. Balance-sheet pressure and volatile earnings keep the setup constructive rather than aggressive.
HCA Healthcare delivered strong revenue, earnings, and cash flow growth despite a choppy quarter. The stock looks attractively valued, but its heavy debt load keeps the risk profile elevated.
PayPal looks like a classic value-and-turnaround setup: growth is modest, but scale, cash flow, and a low multiple leave room for upside if execution improves. The report highlights improving Venmo and enterprise momentum alongside pressure in branded checkout economics.
Biogen’s business has stabilized, with growth products and LEQEMBI helping offset legacy MS pressure. The stock still looks reasonably priced for a selective Buy as cash flow and mix improve.
Generate AI research on any ticker — grades, price targets, and full analysis in minutes.
Open the Generator